New inhibitors of poly(ADP-ribose) polymerase (PARP)

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 11, 2004, Pages 1531-1551

  Peukert, Stefan ^a   Schwahn, Uwe ^b  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^b NONE

Author keywords

Cancer; Inflammation; Ischaemia reperfusion injury; Neurodegeneration; PARP inhibitor; PARP 1; PARP 2; PARS inhibitor; Poly(ADP ribose synthetase (PARS); Poly(ADP ribose) polymerase (PARP)

Indexed keywords

2 (4 HYDROXYPHENYL)BENZIMIDAZOLE 4 CARBOXAMIDE; 2 METHYL 3,5,7,8 TETRAHYDROTHIOPYRANO[4,3 D]PYRIMIDIN 4 ONE; 2 METHYLBENZIMIDAZOLE 4 CARBOXAMIDE; 5,6 DIHYDROIMIDAZO[4,5,1 J K][1,4]BENZODIAZOPIN 7[4H] ONE; 5[H] PHENANTHRIDIN 6 ONE; 8 FLUORO 5[H] PHENANTHRIDIN 6 ONE 3 SULFONIC ACID; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; ADENOSINE DIPHOSPHATE RIBOSE; AG 14361; ANTINEOPLASTIC AGENT; CEP 6800; DIHYDROBENZO[DE]ISOQUINOLINON 1 ONE; DNA; DNA BINDING PROTEIN; FR 247304; FR 255595; GPI 6150; INO 1001; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NEUROPROTECTIVE AGENT; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NU 1064; NU 1076; NU 1085; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOACTIVE AGENT;

BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER THERAPY; CARDIOPLEGIA; CATALYSIS; CELL DAMAGE; CELL DEATH; CLINICAL TRIAL; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; ENERGY CONSUMPTION; ENZYME ACTIVATION; ENZYME DEGRADATION; GENETIC STABILITY; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; ISCHEMIA; NERVE CELL LESION; NERVE DEGENERATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OCCLUSIVE CEREBROVASCULAR DISEASE; PARKINSON DISEASE; PATENT; PROTEIN POLYMERIZATION; REPERFUSION INJURY; REVIEW; SOLID TUMOR; STREPTOZOCIN DIABETES;

EID: 8444230439     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.11.1531     Document Type: Review

References (102)

1. ELIASSON MJ, SAMPEI K, MANDIR AS et al.: Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat. Med. (1997) 3: 1089-1095.
2. AFFAR EB, SHAH RG, POIRIER GG: Poly(ADP-ribose) turnover in quail myoblast cells: relation between the polymer level and its catabolism by glycohydrolase. Mol. Cell Biochem. (1999) 193: 127-135.
3. MIWA M, TANAKA M, MATSUSHIMA T, SUGIMURA T: Purification and properties of glycohydrolase from calf thymus splitting ribose-ribose linkages of poly(adenosine diphosphate ribose). J. Biol. Chem. (1974) 249:3475-3482.
4. SMITH S: The world according to PARP. Trends Biochem. Sci (2001) 26:174-179.
5. MA Q, BALDWIN KT, RENZELLI AJ, MCDANIEL A, DONG L: TCDD-inducible poly(ADP-ribose) polymerase: a novel response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Biophys. Res. Commun. (2001) 289:499-506.
6. CHAMBON P, WEILL JD, MANDEL P: Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. (1963) 11:39-43.
7. AME JC, ROLLI V, SCHREIBER V et al.: PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J. Biol. Chem. (1999) 274:17860-17868.
8. SALLMANN FR, VODENICHAROV MD, WANG ZQ, POIRIER GG: Characterization of sPARP-1. An alternative product of PARP-1 gene with poly(ADP-ribose) polymerase activity independent of DNA strand breaks. J. Biol. Chem. (2000) 275:15504-15511.
9. KRUPITZA G, CERUTTI P: Poly(ADP-ribosylation) of histones in intact human keratinocytes. Biochemistry (1989) 28:4054-4060.
10. KUMARI SR, MENDOZA-ALVAREZ H, ALVAREZ-GONZALEZ R. Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA damage: covalent poly(ADP-ribosyl)ation of p53 by exogenous PARP and noncovalent binding of p53 to the M(r) 85,000 proteolytic fragment. Cancer Res. (1998) 58:5075-5078.
11. YOSHIHARA K, ITAYA A, TANAKA Y et al.: Inhibition of DNA polymerase α, DNA polymerase β, terminal deoxynucleotidyl transferase, and DNA ligase II by poly(ADP-ribosyl)ation reaction in vitro. Biochem. Biophys. Res. Commun. (1985) 128:61-67.
12. DARBY MK, SCHMITT B, JONGSTRA-BILEN J, VOSBERG HP: Inhibition of calf thymus Type II DNA topoisomerase by poly(ADP-ribosylation). EMBO J. (1985) 4:2129-2134.
13. MASSON M, NIEDERGANG C, SCHREIBER V, MULLER S, MENISSIER-DE MURCIA J, DE MURCIA G: XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell Biol. (1998) 18:3563-3571.
14. MENISSIER DM, RICOUL M, TARTIER L et al.: Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. (2003) 22:2255-2263.
15. SHALL S, DE MURCIA G: Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res. (2000) 460:1-15.
16. SIMBULAN-ROSENTHAL CM, ROSENTHAL DS, LUO R, LI JH, ZHANG J, SMULSON ME: Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy. Nucleic Acids Res. (2001) 29:841-849.
17. BURKLE A, HEILBRONN R, ZUR HH: Potentiation of carcinogen-induced methotrexate resistance and dihydrofolate reductase gene amplification by inhibitors of poly(adenosine diphosphate-ribose) polymerase. Cancer Res. (1990) 50:5756-5760.
18. WALDMAN AS, WALDMAN BC: Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation). Nucleic Acids Res. (1991) 19: 943-5947.
19. AUGUSTIN A, SPENLEHAUER C, DUMOND H et al.: PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression. J. Cell Sci. (2003) 116: 551-1562.
20. JOHANSSON M: A human poly(ADP-ribose) polymerase gene family (ADPRTL): cDNA cloning of two novel poly(ADP-ribose) polymerase homologues. Genomics (1999) 57:442-445.
21. KANAI M, UCHIDA M, HANAI S, UEMATSU N, UCHIDA K, MIWA M: Poly(ADP-ribose) polymerase localizes to the centrosomes and chromosomes. Biochem. Biophys. Res. Commun. (2000) 278:385-389.
22. KANAI M, TONG WM, SUGIHARA E, WANG ZQ, FUKASAWA K, MIWA M: Involvement of poly(ADP-Ribose) polymerase 1 and poly(ADP-Ribosyl)ation in regulation of centrosome function. Mol. Cell Biol. (2003) 23: 451-2462.
23. KAIMINKER PG, KIM SH, TAYLOR RD et al.: TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression. J. Biol. Chem. (2001) 276: 5891-35899.
24. SMITH S, GIRIAT I, SCHMITT A, DE LANGE T: Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science (1998) 282:1484-1487.
25. SMITH S, DE LANGE T: Tankyrase promotes telomere elongation in human cells. Curr. Biol. (2000) 10:1299-1302.
26. DYNEK JN, SMITH S: Resolution of sister telomere association is required for progression through mitosis. Science (2004) 304: 7-100.
27. COOK BD, DYNEK JN, CHANG W, SHOSTAK G, SMITH S: Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol. Cell Biol. (2002) 22:332-342.
28. CHI NW, LODISH HF: Tankyrase is a golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles. J. Biol. Chem. (2000) 275:38437-38444.
29. SMITH S, DE LANGE T: Cell cycle dependent localization of the telomeric PARP, tankyrase, to nuclear pore complexes and centrosomes. J. Cell Sci. (1999) 112(21):3649-3656.
30. KICKHOEFER VA, SIVA AC, KEDERSHA NL et al.: The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J. Cell Biol. (1999) 146:917-928.
31. KICKHOEFER VA, RAJAVEL KS, SCHEFFER GL, DALTON WS, SCHEPER RJ, ROME LH: Vaults are upregulated in multidrug-resistant cancer cell lines. J. Biol. Chem. (1998) 273:8971-8974.
32. SCHROEIJERS AB, SIVA AC, SCHEFFER GL et al.: The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines. Cancer Res. (2000) 60:1104-1110.
33. MOSSINK MH, VAN ZON A, FRANZEL-LUITEN E et al.: Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res. (2002) 62: 298-7304.
34. MOSSINK MH, DE GROOT J, VAN ZON A et al.: Unimpaired dendritic cell functions in MVP/LRP knockout mice. Immunology (2003) 110:58-65.
35. MA Q: Induction and superinduction of 2,3,7,8-tetrachlorodibenzo-rho-dioxin-inducible poly(ADP-ribose) polymerase: role of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator transcription activation domains and a labile transcription repressor. Arch. Biochem. Biophys. (2002) 404:309-316.
36. MATSUO R, MURAYAMA A, SAITOH Y, SAKAKI Y, INOKUCHI K: Identification and cataloging of genes induced by long-lasting long-term potentiation in awake rats. J. Neurochem. (2000) 74: 239-2249.
37. KURT RA, BERNSTEIN RM, SCHLUTER SF, PARK J, MARCHALONIS JJ, AKPORIAYE E: The isolation and identification of genes differentially expressed in progressing versus regressing tumours through subtractive hybridization. (1996) GenBank acc. no.: U55178.
38. CHIARUGI A, MOSKOWITZ MA: Cell biology. PARP-1 - a perpetrator of apoptotic cell death? Science (2002) 297: 00-201.
39. YU SW, WANG H, POITRAS MF et al.: Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 297:259-263.
40. COSI C: New inhibitors of poly(ADP-ribose) polymerase and their potential therapeutic targets. Expert Opin. Ther. Patents (2002) 12:1047-1071.
41. SZABO C, DAWSON VL: Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol. Sci. (1998) 19:287-298.
42. TENTORI L, PORTARENA I, GRAZIANI G: Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol. Res. (2002) 45:73-85.
43. VIRAG L, SZABO C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. (2002) 54:375-429.
44. PIEPER AA, VERMA A, ZHANG J, SNYDER SH: Poly(ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol. Sci. (1999) 20:171-181.
45. CHIARUGI A: Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol. Sci (2002) 23:122-129.
46. HONG SJ, DAWSON TM, DAWSON VL: Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol. Sci. (2004) 25:259-264.
47. BERGER NA: Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res. (1985) 101:4-15.
48. HA HC, SNYDER SH: Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc. Natl. Acad. Sci. USA (1999) 96:13978-13982.
49. FERRARIS D, FICCO RP, DAIN D et al.: Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries. Bioorg. Med. Chem. (2003) 11:3695-3707.
50. FERRARIS D, KO YS, PAHUTSKI T et al.: Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries. J. Med. Chem. (2003) 46:3138-3151.
51. KHAN TA, RUEL M, BIANCHI C et al.: Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. J. Am. Coll. Surg. (2003) 197:270-277.
52. KOMJATI K, MABLEY JG, VIRAG L, SOUTHAN GJ, SALZMAN AL, SZABO C: Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int. J. Mol. Med. (2004) 13:373-382.
53. SHIEH WM, AME JC, WILSON MV et al.: Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J. Biol. Chem. (1998) 273:30069-30072.
54. AME JC, ROLLI V, SCHREIBER V et al.: PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J. Biol. Chem. (1999) 274:17860-17868.
55. SCHREIBER V, AME JC, DOLLE P et al.: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem. (2002) 277: 3028-23036.
56. PASCHEN W, OLAH L, MIES G: Effect of transient focal ischemia of mouse brain on energy state and NAD levels: no evidence that NAD depletion plays a major role in secondary disturbances of energy metabolism. J. Neurochem. (2000) 75:1675-1680.
57. LE PAGE C, SANCEAU J, DRAPIER JC, WIETZERBIN J: Inhibitors of ADP-ribosylation impair inducible nitric oxide synthase gene transcription through inhibition of NF-κB activation. Biochem. Biophys. Res. Commun. (1998) 243:451-457.
58. OLIVER FJ, MENISSIER-DE MURCIA J, NACCI C et al.: Resistance to endotoxic shock as a consequence of defective NF-κB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J (1999) 18: 4446-4454.
59. SANCAR A, LINDSEY-BOLTZ LA, UNSAL-KACCMAZ K, LINN S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Ann. Rev. Biochem. (2004) 73:39-85.
60. SUAREZ-PINZON WL, MABLEY JG, POWER R, SZABO C, RABINOVITCH A: Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes (2003) 52:1683-1688.
61. SORIANO FG, PACHER P, MABLEY J, LIAUDET L, SZABO C: Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ. Res. (2001) 89: 84-691.
62. SORIANO FG, VIRAG L, JAGTAP P et al.: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat. Med. (2001) 7:108-113.
63. MURAKAMI K, ENKHBAATAR P, SHIMODA K et al.: Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock (2004) 21:126-133.
64. CHIARUGI A: Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br. J. Pharmacol. (2002) 137:761-770.
65. VIRAG L, BAI P. BAK I et al.: Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma. Med. Sci. Monit. (2004) 10: R77-BR83.
66. LIAUDET L, PACHER P, MABLEY JG et al.: Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am. J. Respir. Crit. Care Med. (2002) 165:372-377.
67. VERES B, RADNAI B, GALLYAS F JR. et al.: Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J. Pharmacol. Exp. Ther. (2004) 310:247-255.
68. VERES B, GALLYAS F JR, VARBIRO G et al.: Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase-1 inhibitor in endotoxin-induced septic shock. Biochem. Pharmacol. (2003) 65:1373-1382.
69. CALABRESE CR, ALMASSY R, BARTON S et al.: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst. (2004) 96: 6-67.
70. SUH SW, AOYAMA K, CHEN Y et al.: Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. J. Neurosci. (2003) 23:10681-10690.
71. MIKNYOCZKI SJ, JONES-BOLIN S, PRITCHARD S et al.: Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther (2003) 2:371-382.
72. TENTORI L, LEONETTI C, SCARSELLA M et al.: Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood (2002) 99:2241-2244.
73. RUF A, MENNISSIER DM, DE MURCIA G, SCHULZ GE: Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl. Acad. Sci. USA (1996) 93:7481-7485.
74. + binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry (1998) 37:3893-3900.
75. OLIVER AW, AME JC, ROE SM, GOOD V, DE MURCIA G, PEARL LH: Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucleic Acids Res. (2004) 32:456-464.
76. KINOSHITA T, NAKANISHI I, WARIZAYA M et al.: Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett. (2004) 556:43-46.
77. PERKINS E, SUN D, NGUYEN A et al.: Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast. Cancer Res. (2001) 61 4175-4183.
78. KERRIGAN F, COCKCROFT X, DILLON.K.J. et al.: Imide-substituted 4-benzyl-2H-phthalazin-1-ones: potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). 12th RSC-SCI Medicinal Chemistry Symposium. Cambridge, UK (2003).
79. BANASIK M, UEDA K: Inhibitors and activators of ADP-ribosylation reactions. Mol. Cell Biochem. (1994) 138: 185-197.
80. LI JH, ZHANG J: PARP inhibitors. IDrugs (2001) 4: 04-812.
81. SOUTHAN GJ, SZABO C: Poly(ADP-ribose) polymerase inhibitors. Curr. Med. Chem. (2003) 10:321-340.
82. CANAN KOCH SS, THORESEN LH, TIKHE JG et al.: Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J. Med. Chem. (2002) 45:4961-4974.
83. LI H, GOLDSTEIN BM: Carboxamide group conformation in the nicotinamide and thiazole-4-carboxamide rings: implications for enzyme binding. J. Med. Chem. (1992) 35:3560-3567.
84. SUTO MJ, TURNER WR, ARUNDEL-SUTO CM, WERBEL LM, SEBOLT-LEOPOLD JS: Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des. (1991) 6:107-117.
85. BANASIK M, KOMURA H, SHIMOYAMA M, UEDA K: Specific inhibitors of poly(ADP-ribose) synthetase and mono (ADP-ribosyl) transferase. J. Biol. Chem. (1992) 267:1569-1575.
86. GRIFFIN RJ, SRINIVASAN S, BOWMAN K et al.: Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). J. Med. Chem. (1998) 41:5247-5256.
87. SHINKWIN AE, WHISH WJ, THREADGILL MD: Synthesis of thiophenecarboxamides, thieno[3,4-c]pyridin-4(5H)-ones and thieno[3,4-d]pyrimidin-4(3H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP). Bioorg. Med. Chem. (1999) 7:297-308.
88. BOWMAN KJ, WHITE A, GOLDING BT, GRIFFIN RJ, CURTIN NJ: Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br. J. Cancer (1998) 78:1269-1277.
89. WHITE AW, ALMASSY R, CALVERT AH et al.: Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase. J. Med. Chem. (2000) 43:4084-4097.
90. ABDELKARIM GE, GERTZ K, HARMS C et al.: Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int. J. Mol. Med. (2001) 7:255-260.
91. IWASHITA A, YAMAZAKI S, MIHARA K et al.: Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Pharmacol. Exp. Ther. (2004) 309:1067-1078.
92. IWASHITA A, TOJO N, MATSUURA S et al.: A novel and potent PARP-1 inhibitor, 5-chloro-2-[3-(4-phenyl-3, 6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone (FR247304), attenuates neuronal damage in vitro and in vivo models of cerebral ischemia. J. Pharmacol. Exp. Ther. (2004) 310: 25-436.
93. STEINHAGEN H, GERISCH M, MITTENDORF J, SCHLEMMER KH, ALBRECHT B: Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett. (2002) 12:3187-3190.
94. SHIGA F, TAKANO Y, KANDA T et al.: Synthesis of novel isoquinolinone derivatives as highly potent PARP inhibitors. 227th National meeting of the American Chemical Society. Anaheim, CA USA. MEDI-288 (2004).
95. WHITE AW, CURTIN NJ, EASTMAN BW et al.: Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:2433-2437.
96. PELLICIARI R, CAMAIONI E, CONSTANTINO G et al.: Towards new neuroprotective agents: design and synthesis 4H-thieno[2,3-c isoquinolin-5-one derivatives as potent PARP-1 inhibitors. Il Farmaco (2003) 58:851-858.
97. MURAKAMI K, ENKHBAATAR P, SHIMODA K et al.: Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock (2004) 21:126-133.
98. BROCK WA, MILAS L, BERGH S, LO R, SZABO C, MASON KA: Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett. (2004) 205:155-160.
99. MUSICK KY, WEINTRAUB PM, EASTWOOD P et al.: Design, synthesis and SAR evaluation of novel inhibitors of poly(ADP-ribose)polymerase (PARP). 226th National meeting of the American Chemical Society, New York, NY, MEDI-121. (2003).
100. JAGTAP PG, SOUTHAN GJ, BALOGLU E et al.: The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett. (2004) 14:81-85.
101. CHIARUGI A, MELI E, CALVANI M et al.: Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J. Pharmacol. Exp. Ther. (2003) 305:943-949.
102. IWASHITA A, MIRARA K, YAMAZAKI S et al.: A new poly(ADP-ribose) polymerase inhibitor, FR-261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice. J. Pharmacol. Exp. Ther. (2004) 310:1114-1124.